Skip to main content

Table 4 Echocardiographic measurements

From: The effect of treatment with pimobendan in dogs with preclinical mitral valve disease – a placebo-controlled double-blinded crossover study

 

pimobendan (A) treatment

placebo (B) treatment

baseline

day 90

day 180

baseline

day 90

day 180

LA/Ao

1.33 (± 0.18)

1.35 (± 0.14)

1.37 (± 0.18)

1.3 (± 0.2)

1.37 (± 0.15)

1.37 (± 0.2)

LVIDDn

1.49 (± 0.15)

1.41 (± 0.19)

1.39 (± 0.17)

1.47 (± 0.19)

1.45 (± 0.18)

1.45 (± 0.18)

FS %

35.38 (± 10.42)

39.11 (± 8.01)

35.82 (± 5.05)

33.82 (± 7.87)

34.11 (± 8.98)

32.37 (± 9.04)

  1. FS % fractional shortening in per cent; Echocardiographic measurements for n = 15 dogs at baseline- and follow-up-investigations at day 90 and 180 in each treatment period
Back to article page

BMC Veterinary Research

ISSN: 1746-6148

Contact us